<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871467</url>
  </required_header>
  <id_info>
    <org_study_id>KW-5001-1</org_study_id>
    <nct_id>NCT01871467</nct_id>
  </id_info>
  <brief_title>Sargramostim for Myeloid Dendritic Cell Deficiency</brief_title>
  <official_title>Sargramostim for Myeloid Dendritic Cell Deficiency - Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have demonstrated a deficiency of blood dendritic cells in patients with
      kidney disease that is associated with the development of viral infections after kidney
      transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell
      levels in patients with kidney disease in the hopes of developing new therapies to prevent
      viral infections after kidney transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target blood myeloid dendritic cell level of &gt; 2.0 x 10&lt;4&gt;/mL</measure>
    <time_frame>2-4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Dendritic Cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Sargramostim administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive sargramostim.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <arm_group_label>Sargramostim administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years &lt; 80 years with diagnosis of end stage renal disease and currently
             undergoing outpatient hemodialysis (HD) at one of the Johns Hopkins
             University-affiliated HD units

        Exclusion Criteria:

          -  Age&lt;18or&gt;80years

          -  History of non-adherence to prescribed HD treatment

          -  Active drug or heavy alcohol use (defined as &gt; 4 drinks/day)

          -  Pregnancy or breast feeding

          -  Active infection (bacterial or viral) or clinically significant infections within the
             past three months (e.g. those requiring hospitalization, or as judged by the PI)

          -  Active malignancy (with the exception of excised non-metastatic basal cell carcinoma
             or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical
             cancer in situ)

          -  Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)

          -  History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) â€¢
             History of lung disease (including moderate-severe chronic obstructive pulmonary
             disease, interstitial lung disease, or asthma)

          -  Known hypersensitivity to yeast-derived products

          -  Hemoglobin &lt; 10 g/dL and hematocrit &lt; 30%.

          -  Abnormal white blood cell (WBC) count at baseline (&lt; 3 or &gt; 12 x 10 cells/mm )

          -  Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications
             (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids, chlorambucil,
             cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating agents will be
             allowed)

          -  Treatment with lithium within 4 weeks of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl L Womer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

